Press

PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale

Jul 21 • 2 min read

PsyBio Therapeutics Corp. (TSXV: PSYB / OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announces that it has received government sanctioned, formal written approval to manufacture PsyBio’s proprietary biosynthetic tryptamines. “PsyBio has worked diligently to achieve formal…

Kernel’s Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects

Jul 20 • 4 min read

Kernel, a leader in non-invasive neuroimaging, announces the publication of their study “Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS,” in the journal Scientific Reports from the Nature Portfolio of Journals. The study, sponsored by Cybin Inc. (NEO:CYBN / NYSE American:CYBN), underscores the ability of Kernel’s Flow1 system to capture…

Filament Health Corp. To List on Nasdaq Through Business Combination With Jupiter Acquisition Corporation

Jul 20 • 6 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter“), a special purpose acquisition company formed for the purpose of acquiring or merging with one of more businesses, today announced they have entered into a definitive agreement, dated July 18, 2023, for a…

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201

Jul 20 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announces that the Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its…

Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast

Jul 20 • 3 min read

Mushrooms Inc. (OTC: MSRM) is pleased to announce that its CEO, Kimberly Carlson, recently appeared on the esteemed Psychedelic Spotlight Podcast to discuss the exciting potential of the industrial mushroom industry. As the first company trading on the US stock market focused on the industrial side of mushrooms, Mushrooms Inc. is leading the way in…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441